One of the fundamental constraints in modern medicine is that therapeutic antibodies — among the most precise biological tools available — cannot naturally cross cell membranes. This means roughly half the proteome, all the proteins operating inside cells, has remained largely beyond their reach. A new platform published in PNAS may substantially redefine that boundary.
Researchers developed a lipid nanoparticle (LNP) delivery system capable of transporting intact, full-length antibodies into the cytosol of living cells — the same core technology that enabled mRNA COVID vaccines, now repurposed for protein cargo. The platform successfully delivered multiple therapeutic antibody types across several cancer cell lines, demonstching inhibition of transcription factors central to inflammatory and oncogenic signaling. In vivo, organ-targeted LNP formulations delivered α-synuclein-specific antibodies in Parkinson's disease models and RelA-targeting immunoglobulins in acute lung injury models — two conditions with vastly different target tissues, suggesting meaningful versatility in the approach.
The significance here is both mechanistic and strategic. Transcription factors like RelA (a subunit of NF-κB) have long been considered 'undruggable' by small molecules due to their flat, featureless binding surfaces, and antibodies have traditionally been excluded simply because they cannot enter cells. If LNP-mediated intracellular antibody delivery proves reproducible and scalable, it could unlock a new therapeutic modality sitting between gene therapy and conventional biologics. The mRNA-LNP field has already demonstrated that lipid nanoparticles can be organ-targeted — liver, lung, and lymph nodes are established — which the researchers appear to leverage here.
Key limitations warrant caution: this is early-stage preclinical work, and translating intracellular antibody delivery from cell lines and rodent disease models to human patients involves substantial hurdles around immunogenicity, endosomal escape efficiency, off-target distribution, and manufacturing complexity. Still, as a proof-of-concept, this represents a potentially paradigm-shifting advance rather than incremental progress — one that reframes what antibody therapeutics can target.